Gemtuzumab ozogamicin (CMA-676), a calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, has recently been introduced clinically as a promising drug for the treatment of patients with acute myeloid leukemia (AML), more than 90% of which express CD33 antigen. However, our recent study suggested that CMA-676 was excreted by a multi-drug-resistance (MDR) mechanism in P-glycoprotein (P-gp)-expressing leukemia cell lines. We analyzed the in vitro effects of CMA-676 on leukemia cells from 27 AML patients in relation to the amount of P-gp, MDR-associated protein 1 (MRP1), CD33 and CD34, using a multi-laser-equipped flow cytometer. The cytocidal effect of CMA-676, estimated by the amount of hypodiploid portion on cell cycle, was inversely related to the amount of P-gp estimated by MRK16 monoclonal antibody (P = 0.004), and to the P-gp function assessed by intracellular rhodamine-123 accumulation in the presence of PSC833 or MS209 as a MDR modifier (P = 0.0004 and P = 0.002, respectively). In addition, these MDR modifiers reversed CMA-676 resistance in P-gp-expressing CD33+ leukemia cells (P = 0.001 with PSC833 and P = 0.0007 with MS209). In CD33+ AML cells from 13 patients, CMA-676 was less effective on CD33+CD34+ than CD33+CD34− cells (P = 0.002). PSC833 partially restored the effect of CMA-676 in CD33+CD34+ cells. These results suggest that the combined use of CMA-676 and a MDR modifier will be more effective on CD33+ AML with P-gp-related MDR.
- Antibody-targeted therapy
- Gemtuzumab ozogamicin (CMA-676)
- MDR modifier
ASJC Scopus subject areas
- Cancer Research